270 afleveringen
- When a paracentral acute middle maculopathy (PAMM) lesion turns up on OCT, is it a retinal finding or a harbinger of something more serious? Barton Blackerby, MD; Matt Starr, MD; and Kyle Kovacs, MD, review a study by Hosovsky and colleagues published in Ophthalmology quantifying the yield of systemic workup in patients with acute isolated PAMM and explore its implications for real-world practice. They discuss how urgency should be stratified for acute versus incidental PAMM findings, what a workup looks like for younger patients presenting without traditional cardiovascular risk factors, and when to bring in subspecialty colleagues.
- Co-hosts Justin C. Muste, MD, and David Fell, MD, discuss the endophthalmitis endgame with Jordan Deaner, MD, a retina specialist at Wills Eye Hospital, and Wills Eye retina fellows Collin Richards, MD, and Erik Massenzio, MD. They share the best timing and treatment approach to patients who present with post-cataract and post-injection endophthalmitis. Shared cases help illustrate when to tap-and-inject (you will never regret doing it, but you might regret not doing it), when vitrectomy is warranted, the challenges of fungal endophthalmitis, and more.
- Could a Wnt pathway agonist match anti-VEGF therapy for DME, and what should we make of a phase 3 trial that hit its anatomic goals but missed its primary visual endpoint? Don D’Amico, MD, reviews one-year results from the phase 2b/3 BRUNELLO study of remigromig (Restoret, Merck/EyeBio), a Wnt pathway agonist, for diabetic macular edema. And Carl Regillo, MD, discusses the phase 3 LUGANO study of EYP-1901 (vorolanib, EyePoint Pharmaceuticals) for wet AMD, which missed its primary endpoint despite reducing treatment burden by 42%.
- The debates at AAO Retina Subspecialty Day have a reputation for examining unresolved issues. Where did the debate on whether wet AMD tolerates fluid land? Avni Finn, MD, joined the show to recap her side of the wet AMD fluid debate—and shared what the opposite side had to argue, too. How well does she buy her own argument?
And Darius Moshfeghi, MD, joins the show to share findings from the SOL-1 study examining OTX-TKI (Ocular Therapeutix) for wet AMD. What did the researchers find? And how did the study authors leverage AI to simulate real-world treatment activity? Join us on this episode to find out. - Does phacovitrectomy improve outcomes over conventional PPV for rhegmatogenous retinal detachment repair in a phakic eyes? Or does it introduce unnecessary complexity? Vaidehi Dedania, MD; Yewlin Chee, MD; and Joshua Uhr, MD, review results from a multicenter cohort study published in Ophthalmology Retina and discuss whether the study's findings have any bearing on real-world decision-making, parse generational differences regarding perceived phacovitrectomy risks, and review whether changes to technology during the course of the study may have affected the findings.
Meer Technologie podcasts
Trending Technologie -podcasts
Over New Retina Radio by Eyetube
New Retina Radio is a place to hear stories about retina that are told nowhere else.
Podcast websiteLuister naar New Retina Radio by Eyetube, AI Report en vele andere podcasts van over de hele wereld met de radio.net-app

Ontvang de gratis radio.net app
- Zenders en podcasts om te bookmarken
- Streamen via Wi-Fi of Bluetooth
- Ondersteunt Carplay & Android Auto
- Veel andere app-functies








































